Literature DB >> 20592075

Reduced fitness in cell culture of HIV-1 with nonnucleoside reverse transcriptase inhibitor-resistant mutations correlates with relative levels of reverse transcriptase content and RNase H activity in virions.

Jiong Wang1, Robert A Bambara, Lisa M Demeter, Carrie Dykes.   

Abstract

Nonnucleoside reverse transcriptase (RT) inhibitors (NNRTIs) are important components of multidrug therapy for HIV-1. Understanding the effect of NNRTI-resistant mutants on virus replication and reverse transcriptase (RT) function is valuable for the development of extended-spectrum NNRTIs. We measured the fitness of six NNRTI-resistant mutants, the K103N, V106A, Y181C, G190A, G190S, and P236L viruses, using a flow cytometry-based cell culture assay. K103N and Y181C viruses had fitness similar to that of the wild type while V106A, G190A, G190S, and P236L viruses had reduced fitness. We also determined the biochemical correlates of fitness by measuring the RNase H and polymerization activities of recombinant mutant RTs and virion-associated RTs. The RNase H activities of recombinant and virion-associated RTs correlated with the relative fitness for each mutant. K103N and Y181C mutants had normal RNase H activity; V106A, G190A, and G190S mutants had moderate reductions in activity; and the P236L mutant had substantially reduced activity. With the exception of the P236L mutant, reduced fitness correlates with low virion-associated polymerization efficiency and reduced RT content. Reduced polymerase function in virions derived from low RT content rather than an intrinsic polymerization defect in each RT protein. In conclusion, severe defects in RNase H activity alone, exemplified by the P236L mutant, appear sufficient to cause a substantial reduction in fitness. For the other NNRTI mutants, reductions in RT content decreased both polymerization and RNase H activity in virions. RNase H reduction was compounded by intrinsic RNase H defects in the mutant RTs.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20592075      PMCID: PMC2937627          DOI: 10.1128/JVI.00618-10

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  42 in total

1.  Replication of phenotypically mixed human immunodeficiency virus type 1 virions containing catalytically active and catalytically inactive reverse transcriptase.

Authors:  J G Julias; A L Ferris; P L Boyer; S H Hughes
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

2.  Impact of clinical reverse transcriptase sequences on the replication capacity of HIV-1 drug-resistant mutants.

Authors:  C Dykes; K Fox; A Lloyd; M Chiulli; E Morse; L M Demeter
Journal:  Virology       Date:  2001-07-05       Impact factor: 3.616

3.  Crystal structure of HIV-1 reverse transcriptase in complex with a polypurine tract RNA:DNA.

Authors:  S G Sarafianos; K Das; C Tantillo; A D Clark; J Ding; J M Whitcomb; P L Boyer; S H Hughes; E Arnold
Journal:  EMBO J       Date:  2001-03-15       Impact factor: 11.598

4.  The sequential mechanism of HIV reverse transcriptase RNase H.

Authors:  M Wisniewski; M Balakrishnan; C Palaniappan; P J Fay; R A Bambara
Journal:  J Biol Chem       Date:  2000-12-01       Impact factor: 5.157

5.  Mutants of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase resistant to nonnucleoside reverse transcriptase inhibitors demonstrate altered rates of RNase H cleavage that correlate with HIV-1 replication fitness in cell culture.

Authors:  R H Archer; C Dykes; P Gerondelis; A Lloyd; P Fay; R C Reichman; R A Bambara; L M Demeter
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

6.  Dynamics of the HIV-1 reverse transcription complex during initiation of DNA synthesis.

Authors:  J M Lanchy; C Isel; G Keith; S F Le Grice; C Ehresmann; B Ehresmann; R Marquet
Journal:  J Biol Chem       Date:  2000-04-21       Impact factor: 5.157

7.  Interactions of reverse transcriptase sequences in Pol with Gag and LysRS in the HIV-1 tRNALys3 packaging/annealing complex.

Authors:  Jenan Saadatmand; Fei Guo; Shan Cen; Meijuan Niu; Lawrence Kleiman
Journal:  Virology       Date:  2008-08-15       Impact factor: 3.616

8.  High-level expression and purification of untagged and histidine-tagged HIV-1 reverse transcriptase.

Authors:  Esther W Hou; Rajendra Prasad; William A Beard; Samuel H Wilson
Journal:  Protein Expr Purif       Date:  2004-03       Impact factor: 1.650

Review 9.  Mechanisms of inhibition of HIV replication by non-nucleoside reverse transcriptase inhibitors.

Authors:  Nicolas Sluis-Cremer; Gilda Tachedjian
Journal:  Virus Res       Date:  2008-03-26       Impact factor: 3.303

10.  Amino acid substitutions at position 190 of human immunodeficiency virus type 1 reverse transcriptase increase susceptibility to delavirdine and impair virus replication.

Authors:  Wei Huang; Andrea Gamarnik; Kay Limoli; Christos J Petropoulos; Jeannette M Whitcomb
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

View more
  26 in total

1.  Nonnucleoside reverse transcriptase inhibitor-resistant HIV is stimulated by efavirenz during early stages of infection.

Authors:  Jiong Wang; Gang Zhang; Robert A Bambara; Dongge Li; Hua Liang; Hulin Wu; Hannah M Smith; Nicholas R Lowe; Lisa M Demeter; Carrie Dykes
Journal:  J Virol       Date:  2011-08-10       Impact factor: 5.103

2.  Mutations in HIV-1 gag and pol compensate for the loss of viral fitness caused by a highly mutated protease.

Authors:  Milan Kozísek; Sandra Henke; Klára Grantz Sasková; Graeme Brendon Jacobs; Anita Schuch; Bernd Buchholz; Viktor Müller; Hans-Georg Kräusslich; Pavlína Rezácová; Jan Konvalinka; Jochen Bodem
Journal:  Antimicrob Agents Chemother       Date:  2012-05-29       Impact factor: 5.191

3.  Efavirenz stimulates HIV-1 reverse transcriptase RNase H activity by a mechanism involving increased substrate binding and secondary cleavage activity.

Authors:  John M Muchiri; Dongge Li; Carrie Dykes; Robert A Bambara
Journal:  Biochemistry       Date:  2013-07-09       Impact factor: 3.162

4.  Primer ID Informs Next-Generation Sequencing Platforms and Reveals Preexisting Drug Resistance Mutations in the HIV-1 Reverse Transcriptase Coding Domain.

Authors:  Jessica R Keys; Shuntai Zhou; Jeffrey A Anderson; Joseph J Eron; Lauren A Rackoff; Cassandra Jabara; Ronald Swanstrom
Journal:  AIDS Res Hum Retroviruses       Date:  2015-04-02       Impact factor: 2.205

Review 5.  HIV-1 reverse transcription.

Authors:  Wei-Shau Hu; Stephen H Hughes
Journal:  Cold Spring Harb Perspect Med       Date:  2012-10-01       Impact factor: 6.915

6.  L74V increases the reverse transcriptase content of HIV-1 virions with non-nucleoside reverse transcriptase drug-resistant mutations L100I+K103N and K101E+G190S, which results in increased fitness.

Authors:  Jiong Wang; Dongge Li; Robert A Bambara; Hongmei Yang; Carrie Dykes
Journal:  J Gen Virol       Date:  2013-03-27       Impact factor: 3.891

7.  Reverse transcriptase backbone can alter the polymerization and RNase activities of non-nucleoside reverse transcriptase mutants K101E+G190S.

Authors:  Jiong Wang; Dongge Li; Robert A Bambara; Carrie Dykes
Journal:  J Gen Virol       Date:  2013-06-26       Impact factor: 3.891

8.  Community HIV-1 drug resistance is associated with transmitted drug resistance.

Authors:  M W Tilghman; J Pérez-Santiago; G Osorio; S J Little; D D Richman; W C Mathews; R H Haubrich; D M Smith
Journal:  HIV Med       Date:  2014-01-12       Impact factor: 3.180

Review 9.  Winning the arms race by improving drug discovery against mutating targets.

Authors:  Amy C Anderson
Journal:  ACS Chem Biol       Date:  2011-11-11       Impact factor: 5.100

Review 10.  Reverse Transcription of Retroviruses and LTR Retrotransposons.

Authors:  Stephen H Hughes
Journal:  Microbiol Spectr       Date:  2015-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.